China - CStone Pharmaceuticals , a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today. | June 13, 2023
China - The partner of CStone Pharmaceuticals Servier announced that they will showcase new data for TIBSOVO at the 2023 American Society of Clinical Oncology Annual Meeting and the European. | May 29, 2023
Message :
Required fields
(Reuters) - Swiss drugmaker Novartis paid $650 million to snag an immuno-oncology drug from BeiGene Ltd, the latest Western drugmaker turning to China for must-have assets to fill holes in their cancer portfolios.
Novartis Chief Executive Vas Narasimhan s move, which could bring $1.55 billion in milestone payments and royalties for BeiGene, is also an about-face from comments two years ago when he raised data quality and innovation worries as barriers to Big Pharma s Chinese M&A dreams.
Novartis will co-develop BeiGene s tislelizumab, an anti-PD-1 antibody similar to Keytruda from Merck and Opdivo from Bristol-Myers Squibb which help the immune system attack cancer and which have reaped billions of dollars in sales.